Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1289 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Orexigen adopts corporate realignment

Orexigen adopted this course of action following the receipt of complete response letter from the US Food and Drug Administration on 31 January 2011 regarding the new drug

R-Tech initiates hypotrichosis drug study

The placebo-controlled, double-blind study evaluates the safety, tolerability, and pharmacokinetics of RK-023 in healthy adult male and female volunteers, who will apply the study drug to the eyelid